Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HBW-3210 capsules in mature B-cell lymphoma in China
CTR20233167Phase 2Active
- Sponsor
- Hyperway Pharmaceutical
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HBW-3210 in mature B-cell lymphoma, primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), sponsored by Hyperway Pharmaceutical. Started Oct 2023; status: active.
02
Drugs
HBW-3210
03
Conditions
mature B-cell lymphomaprimary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20233167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233167.